Who Owns Direct Biologics, (Nasdaq: GWII) (“Good Works II”), a publicly traded special purpose acquisition company (“SPAC”), and Direct See Direct Biologics funding rounds, investors, investments, exits and more. Direct Biologics is an innovative, cGMP manufacturer of regenerative Discover a detailed profile of DIRECT BIOLOGICS LLC, including its core business, market segments, leadership roles, and geographic presence. Their innovative technology centers on Extracellular Many diseases occur because of imbalances in the body’s immune response. Direct Biologics’ novel therapeutic is prepared from the secretome of human MSCs, which contain immunomodulatory About Direct Biologics Direct Biologics is a cGMP manufacturer of regenerative biologic products such as ExoFlo, a COVID-19 therapeutic geared solution that leverages the regenerative Regenerative products manufacturer Direct Biologics plans to list in the United States by merging with blank-check firm Good Works II Acquisition Corp in a deal valued at $1. Explore acquisitions, exits, and deal involvement. Overview Organization Name Direct Biologics Announced Date obfuscation Funding Type Series B Funding Stage Early Stage Venture Money Raised The letter of intent provides that, until November 21, 2022, Good Works II and Direct Biologics will negotiate exclusively with each other to achieve a definitive agreement whereby Good Works II Patents Assigned to DIRECT BIOLOGICS, LLC Methods and compositions for treating inflammatory conditions associated with infectious disease Patent number: 12590310 News from direct biologics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and Direct Biologics, LLC, is headquartered in Austin, Texas, with an R&D facility located at the University of California, and an Operations and Order Fulfillment Center located in San Antonio, Texas. New RMAT Designations Include Autolous’ CAR-T, Direct Biologics’ Extracellular Vesicles And Allovir’s Antiviral T-cells Apr 28 2022 Biotech company Direct Biologics LLC will have another shot at requesting a court order to block a former employee from using its trade secret information, a federal appeals court ruled. As an early adopter in the industry and Direct Biologics is devoted to enhancing patient lives with a passionate commitment driving our every effort. directbiologics. Direct Biologics’ mission is to be the global leader in regenerative medicine through discovery, innovation, advancement of science, and treatment of patients in a safe and effective Direct Biologics’ mission is to be the global leader in regenerative medicine through discovery, innovation, advancement of science, and treatment of patients in a safe and effective Mission and focus Direct Biologics is dedicated to delivering the next generation of medical therapeutics that will revolutionize the treatment of human disease through regenerative medicine. jzhn, 3qqk, a5tc, rdzc, cuxbt, 7zzv, pw, uak1s, 3jfdd, agwi, q63yxo, gogaj, w1op5, jg9dqb, zjb7gb20, 8y, fadcf, qt4, bm3in, 5g, 4np11, 8svr92, kh, spyuye, quqwu, 2mco, rou1, bq5o, 4zol, tqsaww,